Human Epidermal Growth Factor Receptor 2-Targeting [


Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
09 2023
Historique:
received: 23 01 2023
revised: 10 05 2023
medline: 4 9 2023
pubmed: 14 7 2023
entrez: 13 7 2023
Statut: ppublish

Résumé

Imaging using the human epidermal growth factor receptor 2 (HER2)-binding tracer

Identifiants

pubmed: 37442602
pii: jnumed.122.265364
doi: 10.2967/jnumed.122.265364
pmc: PMC10478820
doi:

Substances chimiques

ERBB2 protein, human EC 2.7.10.1
ABY-025 0
Gallium Radioisotopes 0
Fluorodeoxyglucose F18 0Z5B2CJX4D
Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Clinical Trial, Phase II Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1364-1370

Informations de copyright

© 2023 by the Society of Nuclear Medicine and Molecular Imaging.

Références

J Nucl Med. 2016 Oct;57(10):1523-1528
pubmed: 27151988
Arch Pathol Lab Med. 2018 Nov;142(11):1364-1382
pubmed: 29846104
Eur J Nucl Med Mol Imaging. 2011 Nov;38(11):1967-76
pubmed: 21748382
Ann Oncol. 2016 Apr;27(4):619-24
pubmed: 26598545
Clin Cancer Res. 2009 Dec 15;15(24):7479-7491
pubmed: 20008848
Eur J Cancer. 2014 Oct;50(15):2519-31
pubmed: 25139492
Lancet. 2017 Mar 25;389(10075):1195-1205
pubmed: 28215665
Mod Pathol. 2012 Jul;25(7):938-48
pubmed: 22388760
N Engl J Med. 2022 Mar 24;386(12):1143-1154
pubmed: 35320644
J Clin Oncol. 2002 Feb 1;20(3):719-26
pubmed: 11821453
Theranostics. 2016 Jan 01;6(2):262-71
pubmed: 26877784
J Nucl Med. 2014 May;55(5):730-5
pubmed: 24665085
Semin Cancer Biol. 2021 Jul;72:185-197
pubmed: 33465471
Lancet Oncol. 2014 Dec;15(13):1493-1502
pubmed: 25456368
EJNMMI Res. 2020 Mar 23;10(1):21
pubmed: 32201920
Oncotarget. 2017 May 25;8(34):56921-56931
pubmed: 28915642
Lancet Oncol. 2021 Jun;22(6):858-871
pubmed: 34019819
Am J Nucl Med Mol Imaging. 2019 Feb 15;9(1):12-23
pubmed: 30911434
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
J Clin Oncol. 2015 Aug 20;33(24):2623-31
pubmed: 26169615
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782

Auteurs

Ali Alhuseinalkhudhur (A)

Division of Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; ali.alkhudhur@igp.uu.se.
Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.

Henrik Lindman (H)

Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.

Per Liss (P)

Division of Radiology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.

Tora Sundin (T)

Clinical Research and Development Unit, Uppsala University Hospital, Uppsala, Sweden.

Fredrik Y Frejd (FY)

Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.
Affibody AB, Solna, Sweden.

Johan Hartman (J)

Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden; and.

Victor Iyer (V)

Division of Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.

Joachim Feldwisch (J)

Affibody AB, Solna, Sweden.

Mark Lubberink (M)

Division of Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Department of Medical Physics, Uppsala University Hospital, Uppsala, Sweden.

Caroline Rönnlund (C)

Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden; and.

Vladimir Tolmachev (V)

Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.

Irina Velikyan (I)

Division of Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.

Jens Sörensen (J)

Division of Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH